Last reviewed · How we verify
NCT07401017
The Effects of Rosuvastatin on Running Training Adaptation and Safety
NA trial testing Rosuvastatin in Dyslipidemia in 40 participants. Not yet recruiting.
31 August 2026
Quick facts
| Lead sponsor | Taipei Medical University WanFang Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 40 |
| Start date | 1 March 2026 |
| Primary completion | 31 August 2026 |
| Estimated completion | 31 October 2026 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Rosuvastatin (rosuvastatin) — full drug profile →
Conditions studied
- Dyslipidemia — all drugs for Dyslipidemia →
- Long-Distance Running — all drugs for Long-Distance Running →
- Endurance Training — all drugs for Endurance Training →
- Statin-Associated Muscle Symptoms — all drugs for Statin-Associated Muscle Symptoms →
Sponsor
Taipei Medical University WanFang Hospital
Who can join
18 and older, any sex, with Dyslipidemia or Long-Distance Running. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Statins lower low-density lipoprotein cholesterol (LDL-C) and help prevent atherosclerotic cardiovascular disease, but some users develop statin-associated muscle symptoms (SAMS) such as soreness, stiffness, weakness, or elevated creatine kinase (CK). These symptoms may be more noticeable during exercise. Regular long-distance running improves cardiopulmonary fitness-VO₂max, aerobic threshold (AT), and respiratory compensation point (RCP)-mainly through mitochondrial and metabolic adaptations. Prior studies suggest that lipophilic statins like simvastatin may blunt these adaptations, while hydrophilic statins such as rosuvastatin may have a smaller impact. However, prospective data in habitual endurance runners are limited. This randomized controlled trial will examine how rosuvastatin affects cardiopulmonary fitness improvements and muscle tolerance in individuals who run at least three times per week and meet clinical criteria for statin therapy. After informed consent and baseline cardiopulmonary exercise testing (CPET), participants will be randomized to rosuvastatin 10 mg daily or no statin therapy for three months. Both groups will maintain their usual training routines, and training load will be recorded using heart-rate-based TRIMP. CPET will be repeated monthly to assess changes in VO₂max, AT, and RCP, and muscle enzymes and SAMS will be evaluated at each visit. The study aims to clarify whether rosuvastatin influences endurance-related physiological adaptations or increases muscle symptoms in regular long-distance runners.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07401017
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rosuvastatin
Trials testing the same drug.
- NCT07474649 — A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events · Phase 3 · not yet recruiting
- NCT07534592 — A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants · Phase 1 · not yet recruiting
- NCT07515339 — A Study to Learn More About How Safe Nurandociguat is and How it Affects the Way the Body Processes Rosuvastatin and Dab · Phase 1 · not yet recruiting
- NCT07303816 — Statins to Prevent Cancer Associated Blood Clots · Phase 4 · not yet recruiting
- NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
Other recruiting trials for Dyslipidemia
Currently open trials in the same condition.
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07268781 — Impact of Golden Rice-Piper Crocatum Cookies on Lipid Control in Diabetes Mellitus Patients · NA · active not recruiting
- NCT06919302 — The Effect of a Digital Heart Health App and Lifestyle Intervention for Heart Disease in Primary Care. · NA · recruiting
- NCT07162441 — A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and · Phase 1 · recruiting
- NCT07043166 — Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens · recruiting
Other Taipei Medical University WanFang Hospital trials
Trials by the same sponsor.
- NCT07293442 — Pelvic Floor Muscle Exercise for Lower Urinary Tract Symptoms After Surgery for Benign Prostatic Hyperplasia. · NA · recruiting
- NCT07150182 — Shared Decision-Making for Families in Critical Dialysis Initiation · NA · not yet recruiting
- NCT06834425 — Efficacy of NSAID Peritendinous Injection for Acute Tendinitis · NA · active not recruiting
- NCT06862297 — Prospective Study Between Polysomnography (PSG) and Novel Ultrasonic Jaw Tracking Device in Patients with Sleep Apnea · NA · recruiting
- NCT06318468 — The Effectiveness of Various Teaching Methods to Enhance the Comprehensive Nursing Assessment Skills of New Nurses · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07401017 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taipei Medical University WanFang Hospital
- Last refreshed: 10 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07401017.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing